tiprankstipranks
Trending News
More News >
Immunome (IMNM)
NASDAQ:IMNM
US Market
Advertisement

Immunome (IMNM) AI Stock Analysis

Compare
337 Followers

Top Page

IMNM

Immunome

(NASDAQ:IMNM)

Select Model
Select Model
Select Model
Neutral 53 (OpenAI - 4o)
Rating:53Neutral
Price Target:
$12.00
▲(5.82% Upside)
Immunome's stock score is primarily influenced by its financial performance, which shows significant challenges but some potential for improvement. The technical analysis is positive, indicating bullish momentum. However, the valuation is poor due to negative earnings, which weighs down the overall score.
Positive Factors
Revenue Growth
Immunome's revenue growth indicates increasing market acceptance and potential for scaling its therapeutic offerings, enhancing long-term business prospects.
Cash Flow Improvement
Improving free cash flow suggests better cash management and operational efficiency, providing more resources for R&D and strategic investments.
Low Leverage
Minimal leverage reduces financial risk, offering Immunome flexibility to invest in growth opportunities without significant debt burden.
Negative Factors
Negative Profit Margins
Persistent negative profit margins highlight ongoing operational challenges, which may hinder profitability and require strategic adjustments.
Negative Return on Equity
A negative ROE indicates that the company is not generating sufficient returns on shareholder investments, which could deter future investment.
Operational Inefficiencies
Negative margins suggest inefficiencies in operations, potentially limiting the company's ability to achieve sustainable profitability and growth.

Immunome (IMNM) vs. SPDR S&P 500 ETF (SPY)

Immunome Business Overview & Revenue Model

Company DescriptionImmunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
How the Company Makes MoneyImmunome makes money primarily through the development and commercialization of its proprietary antibody-based therapeutics. The company generates revenue through strategic partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These partnerships often involve milestone payments and royalties from the commercialization of co-developed products. Immunome may also secure funding through government grants and research funding to support its R&D efforts. Additionally, as its pipeline products advance through clinical trials and potentially reach regulatory approval, Immunome can generate significant revenues from product sales.

Immunome Financial Statement Overview

Summary
Immunome faces substantial financial difficulties, with persistent losses impacting profitability and cash flow. While the balance sheet remains robust due to strong equity, operational inefficiencies need addressing to improve financial health.
Income Statement
45
Neutral
Immunome's income statement reflects significant challenges, with consistent net losses and negative EBIT and EBITDA margins over the periods reported. Despite some revenue growth from 2024 to TTM (Trailing-Twelve-Months), the company operates with negative profitability metrics, indicating ongoing operational difficulties.
Balance Sheet
55
Neutral
The balance sheet shows a strong equity base with a favorable debt-to-equity ratio, suggesting financial stability. However, the company’s high cash position is offset by recurring net losses, which could pressure equity if operations do not improve.
Cash Flow
50
Neutral
Immunome's cash flow statement highlights negative operating cash flows, though financing activities have supported liquidity. Free cash flow is persistently negative, which is concerning for long-term sustainability unless the trend reverses.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue12.59M9.04M14.02M0.000.000.00
Gross Profit12.59M9.04M14.02M-631.00K-755.00K-755.00K
EBITDA-187.92M-151.35M-28.00M-36.27M-23.95M-17.04M
Net Income-212.39M-292.96M-106.81M-37.51M-24.71M-17.84M
Balance Sheet
Total Assets296.29M240.24M148.54M24.05M57.92M44.52M
Cash, Cash Equivalents and Short-Term Investments268.04M217.30M138.14M20.32M49.23M39.77M
Total Debt4.14M4.83M1.65M291.00K317.00K613.00K
Total Liabilities27.02M59.08M28.66M7.39M9.74M3.18M
Stockholders Equity269.27M181.16M119.88M16.65M48.19M41.34M
Cash Flow
Free Cash Flow-186.17M-117.97M-8.40M-28.94M-18.30M-12.72M
Operating Cash Flow-178.68M-110.79M-7.57M-28.69M-18.23M-12.13M
Investing Cash Flow-25.23M-85.06M-30.48M-248.00K-79.00K-586.00K
Financing Cash Flow182.56M240.53M116.41M32.00K27.77M49.94M

Immunome Technical Analysis

Technical Analysis Sentiment
Positive
Last Price11.34
Price Trends
50DMA
10.18
Positive
100DMA
9.58
Positive
200DMA
9.39
Positive
Market Momentum
MACD
0.44
Negative
RSI
58.79
Neutral
STOCH
73.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNM, the sentiment is Positive. The current price of 11.34 is above the 20-day moving average (MA) of 10.15, above the 50-day MA of 10.18, and above the 200-day MA of 9.39, indicating a bullish trend. The MACD of 0.44 indicates Negative momentum. The RSI at 58.79 is Neutral, neither overbought nor oversold. The STOCH value of 73.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMNM.

Immunome Risk Analysis

Immunome disclosed 78 risk factors in its most recent earnings report. Immunome reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Immunome Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
53
Neutral
$987.09M-81.20%16.74%59.89%
53
Neutral
$867.49M-8.91-37.28%-37.09%58.96%
48
Neutral
$1.09B-12.87-15.91%83.36%22.27%
47
Neutral
$899.60M-10.64-33.91%11877.28%63.14%
47
Neutral
$887.30M-6.00-107.86%-42.84%-17.32%
33
Underperform
$957.20M-3.487.58%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IMNM
Immunome
11.47
-1.70
-12.91%
GERN
Geron
1.38
-2.94
-68.06%
IMTX
Immatics
9.00
-1.86
-17.13%
TNGX
Tango Therapeutics
7.98
1.00
14.33%
TSHA
Taysha Gene Therapies
4.88
2.87
142.79%
SANA
Sana Biotechnology
3.70
-0.53
-12.53%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 27, 2025